R
enal cell carcinoma is the tenth leading cause of cancer death among men in the United States, accounting for 3% of malignancies (Jemal et al., 2003) . Of the forms of kidney cancer, renal cell carcinoma accounts for 85% of diagnosed cases (Motzer, Bander, & Nanus, 1996) . The average age at diagnosis is 50-70 years, with a 2:1 male to female predominance (Bukowski & Novik, 1997 ). An estimated 31,900 new cases of kidney cancer are projected to be diagnosed in the United States in 2003 (Jemal et al.) , and 25%-33% of these patients will present with metastatic or advanced disease. Although the overall survival is approximately 50% for renal cell carcinoma, the median survival rate for patients with metastatic disease is 7-11 months (Amato, 2000) .
Renal cell carcinoma historically has been considered a single cancer expressing multiple possible histologic appearances. Currently, the disease is viewed as a group of cancers resulting from different genetic abnormalities that have distinct morphologic features, all derived from renal tubular epithelium (Pantuck, Zisman, & Belldegrun, 2001) . The size of the tumors can range from a few centimeters to very large tumors that fill the peritoneal space (Early & Poquette, 2000) . Clear cell carcinoma (also known as conventional or nonpapillary) is the most common type of renal tumor, accounting for approximately 70%-80% of cases. Clear cell renal cell carcinoma is believed to begin in the proximal renal tubule in a hereditary or sporadic form (Pantuck et al.) .
Papillary renal cell carcinoma is the second most common histologic type of renal cell carcinoma, accounting for approximately 10% of cases (Mancilla-Jimenez, Stanley, & Blath, 1976 Conclusions: Treatment with thalidomide, alone and in combination with other therapies, may improve survival for patients with advanced renal cell carcinoma.
Implications for Nursing: Proactive management of adverse effects associated with thalidomide, alone and in combination, may increase patient tolerance and compliance.
Key Points . . . ➤ Despite extensive investigation of systemic chemotherapy, hormonal therapy, and immunotherapy, the survival rate for patients with advanced renal cell carcinoma remains low.
➤ Immunotherapy, including treatment with interferon-a and interleukin-2, is currently the most common treatment for advanced renal cell carcinoma.
➤ Renal cell carcinoma is a highly vascular tumor, and angiogenesis is central to its growth. Antiangiogenic agents such as thalidomide may inhibit tumor growth.
➤ The most common side effects of thalidomide are somnolence, constipation, peripheral neuropathy, and rash.
Goal for CE Enrollees:
To further enhance nurses' knowledge regarding the treatment of advanced renal cell carcinoma.
Objectives for CE Enrollees:
On completion of this CE, the participant will be able to 1. Describe the current treatment options available for patients with renal cell carcinoma. 2. Describe the most common side effects of thalidomide for renal cell carcinoma. 3. Discuss the nursing management of the side effects of thalidomide.
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